Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cassava Sciences, Inc. stock logo
FLNA
Cassava Sciences
$1.00
+3.8%		$1.16
$0.86
▼
$4.98
$48.07M-0.7330,998 shs614,406 shs
Immunic, Inc. stock logo
IMUX
Immunic
$14.30
-1.7%		$14.31
$5.06
▼
$15.84
$194.78M1.41161,567 shs175,478 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$4.27
-3.8%		$4.51
$1.76
▼
$12.46
$198.94M-0.1160,870 shs171,007 shs
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
$6.16
+11.0%		$7.93
$2.80
▼
$8.97
$222.12M0.6337,931 shs2.16 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cassava Sciences, Inc. stock logo
FLNA
Cassava Sciences
0.00%-1.49%-16.39%-23.46%-57.48%
Immunic, Inc. stock logo
IMUX
Immunic
0.00%+2.36%-3.25%+22.96%+46.01%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
0.00%+7.29%-9.53%-27.38%+134.49%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
+10.99%+20.08%-23.95%-29.52%-65.39%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cassava Sciences, Inc. stock logo
FLNA
Cassava Sciences
$1.00
+3.8%		$1.16
$0.86
▼
$4.98
$48.07M-0.7330,998 shs614,406 shs
Immunic, Inc. stock logo
IMUX
Immunic
$14.30
-1.7%		$14.31
$5.06
▼
$15.84
$194.78M1.41161,567 shs175,478 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$4.27
-3.8%		$4.51
$1.76
▼
$12.46
$198.94M-0.1160,870 shs171,007 shs
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
$6.16
+11.0%		$7.93
$2.80
▼
$8.97
$222.12M0.6337,931 shs2.16 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cassava Sciences, Inc. stock logo
FLNA
Cassava Sciences
0.00%-1.49%-16.39%-23.46%-57.48%
Immunic, Inc. stock logo
IMUX
Immunic
0.00%+2.36%-3.25%+22.96%+46.01%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
0.00%+7.29%-9.53%-27.38%+134.49%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
+10.99%+20.08%-23.95%-29.52%-65.39%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cassava Sciences, Inc. stock logo
FLNA
Cassava Sciences
2.00
Hold$5.00402.51% Upside
Immunic, Inc. stock logo
IMUX
Immunic
3.00
Buy$47.57232.67% Upside
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
2.00
Hold$10.50145.90% Upside
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest FLNA, IMUX, NERV, and SBTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/29/2026
Immunic, Inc. stock logo
IMUX
Immunic
LADENBURG THALM/SH SH logo
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
7/20/2026
Cassava Sciences, Inc. stock logo
FLNA
Cassava Sciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/24/2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
5/29/2026
Immunic, Inc. stock logo
IMUX
Immunic
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
5/26/2026
Cassava Sciences, Inc. stock logo
FLNA
Cassava Sciences
Maxim Group logo
Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$5.00
5/22/2026
Immunic, Inc. stock logo
IMUX
Immunic
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform
5/22/2026
Immunic, Inc. stock logo
IMUX
Immunic
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$40.00 ➝ $27.00
5/14/2026
Immunic, Inc. stock logo
IMUX
Immunic
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$19.00
(Data available from 8/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cassava Sciences, Inc. stock logo
FLNA
Cassava Sciences
N/AN/AN/AN/A$1.32 per shareN/A
Immunic, Inc. stock logo
IMUX
Immunic
N/AN/AN/AN/A($0.55) per shareN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/A($3.25) per shareN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/A$7.41 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cassava Sciences, Inc. stock logo
FLNA
Cassava Sciences
-$90.97M-$0.87N/AN/AN/AN/A-58.78%-36.74%N/A
Immunic, Inc. stock logo
IMUX
Immunic
-$97.17M-$5.58N/AN/AN/AN/A-220.75%-132.04%N/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$293.42M-$29.16N/A0.89N/AN/AN/A-32.63%N/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
-$89.48M-$2.42N/AN/AN/AN/A-29.62%-28.20%N/A

Latest FLNA, IMUX, NERV, and SBTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2026Q2 2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$0.1933-$0.14+$0.0533-$0.14N/AN/A
7/29/2026Q2 2026
Cassava Sciences, Inc. stock logo
FLNA
Cassava Sciences
N/A-$0.18N/A-$0.18N/AN/A
5/13/2026Q1 2026
Immunic, Inc. stock logo
IMUX
Immunic
-$0.71-$1.08-$0.37-$1.08N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cassava Sciences, Inc. stock logo
FLNA
Cassava Sciences
N/AN/AN/AN/AN/A
Immunic, Inc. stock logo
IMUX
Immunic
N/AN/AN/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cassava Sciences, Inc. stock logo
FLNA
Cassava Sciences
N/A
2.08
2.08
Immunic, Inc. stock logo
IMUX
Immunic
N/A
4.92
4.92
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/A
17.65
17.65
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/A
67.87
67.87

Institutional Ownership

CompanyInstitutional Ownership
Cassava Sciences, Inc. stock logo
FLNA
Cassava Sciences
38.05%
Immunic, Inc. stock logo
IMUX
Immunic
51.82%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
34.56%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
74.89%

Insider Ownership

CompanyInsider Ownership
Cassava Sciences, Inc. stock logo
FLNA
Cassava Sciences
4.60%
Immunic, Inc. stock logo
IMUX
Immunic
5.49%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
1.70%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
34.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cassava Sciences, Inc. stock logo
FLNA
Cassava Sciences
2048.31 million46.09 millionOptionable
Immunic, Inc. stock logo
IMUX
Immunic
7013.62 million12.87 millionOptionable
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
946.59 million45.80 millionNot Optionable
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
8336.06 million23.65 millionNot Optionable

Recent News About These Companies

Meet the Silverback, the Leader of the Troop
October 17, 2024  |  pbs.orgP
10 Fun Facts About Mountain Gorillas
September 18, 2024  |  nationalgeographic.comN
CapstanTx secures $165 million to deliver precise in vivo cell engineering
July 28, 2024  |  pharmaphorum.comP
ARS Pharmaceuticals Inc (SPRY)
May 11, 2023  |  uk.investing.comhttps://uk.investing.com/equities/silverback-therapeutics-inc
Wild Isles
March 12, 2023  |  wwf.org.ukW
A look back at RNA Therapeutics – day one
February 23, 2023  |  pharmaphorum.comP
SPRY ARS Pharmaceuticals, Inc.
January 24, 2023  |  seekingalpha.comhttps://seekingalpha.com/symbol/SPRY
ARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After Merger
November 22, 2022  |  247wallst.comhttps://247wallst.com/investing/2022/11/22/ars-pharma-ceo-richard-lowenthal-holds-8-silverback-stake-after-merger/
Dr. Sarina Tanimoto Discloses Position in SBTX / Silverback Therapeutics
November 18, 2022  |  nasdaq.comhttps://www.nasdaq.com/articles/dr.-sarina-tanimoto-discloses-position-in-sbtx-silverback-therapeutics
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
November 10, 2022  |  finance.yahoo.comhttps://finance.yahoo.com/news/ars-pharmaceuticals-announces-presentation-clinical-130000987.html?.tsrc=rss
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
November 8, 2022  |  finance.yahoo.comhttps://finance.yahoo.com/news/ars-pharmaceuticals-closes-merger-silverback-210200048.html?.tsrc=rss
Silverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic Reactions
October 28, 2022  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/silverback-fda-accepts-ars-pharm-s-nda-for-neffy-for-treatment-of-allergic-reactions-1031824142
FDA accepts ARS Pharma’s NDA for Neffy
October 24, 2022  |  thepharmaletter.comT
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERI
October 23, 2022  |  kentuckytoday.comK
Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis
October 21, 2022  |  finance.yahoo.comhttps://finance.yahoo.com/news/silverback-therapeutics-inc-announces-fda-113100379.html?.tsrc=rss
Is Silverback Therapeutics Inc (SBTX) Stock a Good Investment?
October 19, 2022  |  aaii.comA
SHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWN
October 12, 2022  |  bakersfield.comB
INVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBT
September 17, 2022  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/investigation-alert-halper-sadeh-llc-investigates-cvet-sbtx-irbt-1031746211
SBTX Silverback Therapeutics, Inc.
September 15, 2022  |  seekingalpha.comhttps://seekingalpha.com/symbol/SBTX/charting
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBT
September 6, 2022  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/shareholder-notice-halper-sadeh-llp-investigates-ftai-sbtx-cvet-gbt-1031726462

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cassava Sciences stock logo

Cassava Sciences NASDAQ:FLNA

$1.00 +0.04 (+3.75%)
As of 08/7/2026 04:00 PM Eastern

Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.

Immunic stock logo

Immunic NASDAQ:IMUX

$14.30 -0.24 (-1.65%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$14.74 +0.43 (+3.04%)
As of 08/7/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Minerva Neurosciences stock logo

Minerva Neurosciences NASDAQ:NERV

$4.27 -0.17 (-3.83%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$4.25 -0.02 (-0.47%)
As of 08/7/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Silverback Therapeutics stock logo

Silverback Therapeutics NASDAQ:SBTX

$6.16 +0.61 (+10.99%)
As of 08/7/2026

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas